Our laboratory is broadly interested in both genetic and epigenetic modifications associated with exposure and cancer. Epigenetic modifications, including DNA methylation, are being increasingly recognized as is being recognized as important determinants of gene transcriptional regulation that have both heritable and acquired characteristics. Aberrant DNA methylation patterns are among the earliest and most common events in carcinogenesis and recent studies suggest that the epigenetic profile of DNA from a surrogate tissue, peripheral blood, may differ between women with active ovarian cancer compared to women without disease. We have employed genome-wide profiling of DNA methylation in peripheral blood samples from more than 900 women in order to investigate whether the pattern of DNA methylation is associated with breast cancer risk. We have identified a number of methylation sites that are associated with increased risk and are continuing data analysis. A second form of epigenetic modification is miRNA expression. Altered miRNA expression is a central feature of cancer and miRNA expression signatures have been shown to be associated with diagnosis, stage, prognosis, and response to treatment. Expression patterns for cancer show high tissue specificity making them potential markers for cancer screening. Breast cancer specific miRNAs have been shown to correlate with stage, vascular invasion, proliferative index, and ER/PR status. Recently, sufficient levels of miRNAs have been found in human plasma and serum to permit profiling, with sufficient power to distinguish men with metastatic prostate cancer from men without cancer and women with ovarian cancer. We have recently completed assays on more than 400 serum samples from cases and non-cases using the Sister Study cohort and are in the process of data analysis.

Project Start
Project End
Budget Start
Budget End
Support Year
16
Fiscal Year
2012
Total Cost
$1,131,566
Indirect Cost
City
State
Country
Zip Code
O'Brien, Katie M; Sandler, Dale P; Xu, Zongli et al. (2018) Vitamin D, DNA methylation, and breast cancer. Breast Cancer Res 20:70
Herceg, Zdenko; Ghantous, Akram; Wild, Christopher P et al. (2018) Roadmap for investigating epigenome deregulation and environmental origins of cancer. Int J Cancer 142:874-882
Wu, Lang; Shi, Wei; Long, Jirong et al. (2018) A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet 50:968-978
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
O'Brien, Katie M; Sandler, Dale P; Shi, Min et al. (2018) Genome-Wide Association Study of Serum 25-Hydroxyvitamin D in US Women. Front Genet 9:67
O'Brien, Katie M; Sandler, Dale P; Kinyamu, H Karimi et al. (2017) Single-Nucleotide Polymorphisms in Vitamin D-Related Genes May Modify Vitamin D-Breast Cancer Associations. Cancer Epidemiol Biomarkers Prev 26:1761-1771
Wilson, L E; Harlid, S; Xu, Z et al. (2017) An epigenome-wide study of body mass index and DNA methylation in blood using participants from the Sister Study cohort. Int J Obes (Lond) 41:194-199
Harlid, Sophia; Adgent, Margaret; Jefferson, Wendy N et al. (2017) Soy Formula and Epigenetic Modifications: Analysis of Vaginal Epithelial Cells from Infant Girls in the IFED Study. Environ Health Perspect 125:447-452
Michailidou, Kyriaki (see original citation for additional authors) (2017) Association analysis identifies 65 new breast cancer risk loci. Nature 551:92-94
Sandler, Dale P; Hodgson, M Elizabeth; Deming-Halverson, Sandra L et al. (2017) The Sister Study Cohort: Baseline Methods and Participant Characteristics. Environ Health Perspect 125:127003

Showing the most recent 10 out of 46 publications